Frank McCormick sold $13M of BBIO
director at BridgeBio Pharma, Inc.. 198,359 shares at an average of $66.58, traded Oct 29, 2025, filed Oct 31, 2025.
Score components
- +15RoleDirector
- +25Trade size$13.2M at market
- +5Share of holdings soldSold 23% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +15.0%, 3m +23.4%, 6m +9.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001470831-25-000282, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 29, 2025 | SOpen-market sale Common Stockindirect: By the Francis P. McCormick Rev Trust U/A DTD 1/27/201710b5-1 | -111,755 | $65.48 | $7.3M | 766,583 | Oct 31, 2025 |
| Oct 29, 2025 | SOpen-market sale Common Stockindirect: By the Francis P. McCormick Rev Trust U/A DTD 1/27/201710b5-1 | -31,116 | $66.20 | $2.1M | 735,467 | Oct 31, 2025 |
| Oct 29, 2025 | SOpen-market sale Common Stockindirect: By the Francis P. McCormick Rev Trust U/A DTD 1/27/201710b5-1 | -3,497 | $67.52 | $236k | 731,970 | Oct 31, 2025 |
| Oct 29, 2025 | SOpen-market sale Common Stockindirect: By the Francis P. McCormick Rev Trust U/A DTD 1/27/201710b5-1 | -8,598 | $68.50 | $589k | 723,372 | Oct 31, 2025 |
| Oct 29, 2025 | SOpen-market sale Common Stockindirect: By the Francis P. McCormick Rev Trust U/A DTD 1/27/201710b5-1 | -43,393 | $69.24 | $3.0M | 679,979 | Oct 31, 2025 |
Related signals
Other insiders at BridgeBio Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $691k 10,000 shares | -2% | |
| 35Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $3.7M 44,980 shares | -16% | |
| 6Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $160k 2,000 shares | -2% | |
| 33Weak | BridgeBio Pharma, Inc. | Jennifer E. Cook director | $13M 148,589 shares | -95% | |
| 23Weak | BridgeBio Pharma, Inc. | Andrea Ellis director | $1.4M 17,167 shares | -43% | |
| 13Weak | BridgeBio Pharma, Inc. | Hannah Valantine director | $342k 5,004 shares | -35% | |
| 33Weak | BridgeBio Pharma, Inc. | Jennifer E. Cook director | $2.8M 39,363 shares | -372% | |
| 40Moderate | BridgeBio Pharma, Inc. | Jennifer E. Cook director | $6.0M 90,240 shares | -93% | |
| 43Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $5.4M 80,000 shares | -14% | |
| 45Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $1.8M 26,103 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.